Global Alpha Mannosidosis Market to Reach $34.52 Billion by 2029, Growing at 17.6% CAGR

What combination of drivers is leading to accelerated growth in the alpha mannosidosis market?
The alpha mannosidosis market is anticipated to experience growth due to the increasing need for precision medicine. Precision medicine personalizes healthcare with the use of individual genetic, environmental, and lifestyle differences to modify treatment and prevention plans. Advancements in genomic technologies and data analytics, allowing for a deeper understanding of genetic variations and their health implications, are driving the surge in precision medicine. Furthermore, there is a growing demand for custom treatment methods as awareness about the restriction of generic, catch-all approaches increases. For targeted therapies specifically designed for genetic mutations and patient profiles linked to this rare disorder, precision medicine is a crucial element. For example, data from the U.S.-based nonprofit umbrella organization, Personalized Medicine Coalition (PMC), reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023. This marked a significant growth from only six approvals in 2022. Hence, the ongoing surge in demand for precision medicine is fueling the steady growth of the alpha mannosidosis market.

Get Your Alpha Mannosidosis Market Report Here:
https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

What is the projected compound annual growth rate (CAGR) of the alpha mannosidosis market from 2025 to 2034, and what factors influence it?
In recent times, there has been a swift expansion in the market size of alpha mannosidosis. The market, which stood at $15.1 billion in 2024, is projected to surge to $18.02 billion in 2025, witnessing a compound annual growth rate (CAGR) of 19.3%. The unprecedented growth during the historical period can be ascribed to the emergence of new markets, urbanization, heightened demand for synthetic fibers, and government schemes supporting the textile industry.

Expectations have been set for the alpha mannosidosis market size to see a swift expansion over the coming years. By 2029, it's projected to reach a value of $34.52 billion, marking a compound annual growth rate (CAGR) of 17.6%. This growth throughout the anticipated period is attributed to the increase in global population and urbanization, the expansion of e-commerce, a surge in demand for sportswear, the growth of organized retail in developing economies, and the rising influence of social media. The forecast period also hints at major trends like increased adoption of enzyme therapy and hematopoietic stem cell transplantation as well as the use of cisterna magna infusion.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

How are the latest trends influencing the growth of the alpha mannosidosis market?
Leading businesses in the alpha mannosidosis market are striving to produce an enzyme replacement therapy for the rare alpha-mannosidosis disease. This therapy brings in external alpha-mannosidase, which is effective in lessening the buildup of mannose-rich oligosaccharides in multiple tissues and organs. This buildup is a distinctive trait of alpha-mannosidosis, contributing to the disease's detrimental effects. For instance, in February 2023, Chiesi Global Rare Diseases, an American pharmaceutical company, introduced Lamzede (velmanase alfa). This product represents the first enzyme replacement therapy approved in the United States to treat alpha-mannosidosis, a rare genetic disorder characterised by a lack of the alpha-mannosidase enzyme, and its symptoms beyond the central nervous system. Lamzede performs like the human body's alpha-mannosidase enzyme to return regular cellular function to patients. The patients are administered a dose of 10 mg of Lamzede by injection once a week.

What are the major segments of the alpha mannosidosis market and their role in driving growth?
The alpha mannosidosis market covered in this report is segmented -

1) By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Other Therapies
2) By Indication: Type I, Type II, Type III
3) By End-User: Hospitals, Speciality Clinics

Subsegments:
1) By Bone Marrow Transplant (BMT): Autologous BMT, Allogeneic BMT
2) By Enzyme Replacement Therapy (ERT): Recombinant Enzymes, Long-acting Enzyme Formulations
3) By Other Therapies: Symptomatic Treatments, Gene Therapy, Supportive Care

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4093

Which regions are key players in the growth of the alpha mannosidosis market?
North America was the largest region in the alpha mannosidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the alpha mannosidosis market?
Major companies operating in the alpha mannosidosis market include Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Merck, Bristol-Myers Squibb, Novartis AG, Amgen, Centogene, Zymenex A/S, Albumedix Ltd, Kite Pharma, Catalent, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Allergan, PsiOxus Therapeutics, Herantis Pharma Plc, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bayer AG, PTC Therapeutics, Gilead Sciences Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Pfizer S.R.L., AstraZeneca plc, Biogen SA, Sanofi, Adcock Ingram

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=4093&type=smp

What Is Covered In The Alpha Mannosidosis Global Market Report?

•Market Size Forecast: Examine the alpha mannosidosis market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the alpha mannosidosis market for a structured understanding.
•Key Players Overview: Analyze major players in the alpha mannosidosis market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the alpha mannosidosis market.
•Segment Contributions: Evaluate how different segments drive overall growth in the alpha mannosidosis market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the alpha mannosidosis market.
•Industry Challenges: Identify potential risks and obstacles affecting the alpha mannosidosis market.
•Competitive Landscape: Review strategic developments in the alpha mannosidosis market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.